

9-7-2018

# Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Philip Mease  
*Providence St. Joseph Health*

A Kavanaugh

A Reimold

Follow this and additional works at: <https://digitalcommons.psjhealth.org/publications>

 Part of the [Orthopedics Commons](#), and the [Rheumatology Commons](#)

---

## Recommended Citation

Mease, Philip; Kavanaugh, A; and Reimold, A, "Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial." (2018). *Journal Articles and Abstracts*. 1022.

<https://digitalcommons.psjhealth.org/publications/1022>

This Response or Comment is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Journal Articles and Abstracts by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact [digitalcommons@providence.org](mailto:digitalcommons@providence.org).

## Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

---

Mease PJ, Kavanaugh A, Reimold A, *et al.* Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. *RMD Open* 2018;4:e000723. doi: 10.1136/rmdopen-2018-000723corr1

The authors noticed a potential data inconsistency in the published version. The statement regarding the tuberculosis needs to be updated in the first paragraph of the 'Safety' sub-section under the 'Results' section (page 4).

The corrected information on tuberculosis is: No new cases of tuberculosis, and no reactivation of latent tuberculosis were reported.

**Open access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*RMD Open* 2018;4:e000723corr1. doi:10.1136/rmdopen-2018-000723corr1

